Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavapadon in Parkinson's Disease
NCT04760769Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of tavapadon in Parkinson's disease (PD), sponsored by AbbVie Inc.. Started Feb 2021; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04760769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04760769.